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Chemotherapy Dose
Intensity and Survival
in Non-small Cell Lung
Cancer
To the Editor:
Brunetto et al.1 noted that modest
chemotherapy dose reductions did not
have any major impact on survival in
patients with non-small cell lung cancer
(NSCLC) treated with platinum-doublet
chemotherapy and proposed that this
might be due to comorbidities, the impact
of resistance factors such as excision
repair cross-complementing rodent re-
pair deficiency, complementation group
1 (ERCC1) ormarked sensitivity to therapy
in some of the responders. We had previ-
ously converted response rates into hypo-
thetical mean percent tumor cell kill for a
large number of published clinical trials in
NSCLC and had used nonlinear regression
analysis to assess the relationship between
hypothetical log mean cell kill and planned
dose intensity.2 For all platinum combina-
tions assessed, dose-response curves flat-
tened at higher chemotherapy doses. Low
chemotherapy doses were better than no
therapy, but high doses were no better than
low doses.
We had previously hypothesized
that one could infer resistance mecha-
nisms from the shape of the dose-response
curve and that presence of a resistance
factor (e.g., the ERCC1 mentioned by
Brunetto et al.) would give a shoulder on
the dose-response curve when log cell
survival was plotted against linear doses
(analogous to competitive inhibition of
drug effect).3 Mutation of an obligate tar-
get or activating system, would give a
reduced slope on the curve, analogous to
decreased affinity of a drug for its target.3
Deficiency or saturation of something re-
quired for drug effect (e.g., a drug uptake or
activating system, proapoptotic factors, or
cells in a sensitive phase of the cell cycle)
would give an initial downward slope fol-
lowed by a terminal plateau (analogous to
noncompetitive inhibition of drug effect).3
On the basis of our hypothesis and on
our observation of the flattening of the dose-
response curve in NSCLC, we postulated
that our inability to cure metastatic NSCLC
with chemotherapy is ultimately due to de-
ficiency or saturation of something required
for drug efficacy. Furthermore, as no meta-
static epithelial cancer can be cured even by
high-dose chemotherapy, we hypothesized
that all epithelial cancers (e.g., breast, colo-
rectal, and lung cancers) may share a com-
mon reason for this incurability.2 For differ-
ent epithelial cancers or for different patients
with the same type of cancer, a higher or
lowermaximum cell kill may be achievable,
and it may take fewer or more drugs or
higher or lower doses to achieve this maxi-
mum cell kill, but the outcome is ultimately
the same. Resistance factors such as ERCC1
could affect degree of palliation in individual
patients but would not in themselves be
responsible for incurability.
A corollary of this is that, even if all
epithelial cancers are incurable when meta-
static, higher drug doses, or addition ofmore
agents may be useful for relatively sensitive
tumors such as breast and small cell lung
cancer (SCLC) but would be much less
useful for more resistant tumors such as
NSCLC and pancreatic cancer. In keeping
with this, when we did the same type of
analysis in SCLC as in NSCLC, the maxi-
mum achievable cell kill was greater in
SCLC, and cell kill seemed to keep increas-
ing over awider dose range, but amaximum
possible cell kill was nevertheless ultimately
reached.4
A second corollary is that if we
are correct that a common mechanism is
responsible for the incurability of all
epithelial malignancies, then a single
new approach targeting this mechanism
could similarly have a dramatic impact
on outcome of a broad spectrum of ep-
ithelial malignancies.
David J. Stewart, MD, FRCPC
Department of Thoracic/Head and Neck
Medical Oncology
The University of Texas MD Anderson
Cancer Center
Houston, Texas
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Clinical Significance of
Serum Vascular
Endothelial Growth
Factor in Malignant
Pleural Mesothelioma
To the Editor:
We read with great interest the arti-
cle by Yasumitsu et al.,1 who reported the
clinical significance of serum vascular en-
dothelial growth factor (VEGF) in malig-
nant pleural mesothelioma (MPM). VEGF
is an important regulator of angiogene-
sis and might have critical roles in MPM
progression. Demirag et al.2 demon-
strated a significant correlation between
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the VEGF expression on immunohisto-
chemistry and short survival of MPM.
Yasumitsu et al. reported in their ar-
ticle that patients with MPM demonstrated
higher levels of serum VEGF than those of
normal subjects. In addition, they also men-
tioned that patients group of MPM with
higher serum levels of VEGF had shorter
overall survival than those with lower level;
however, in their report, serumVEGF levels
showed significant tendencies to increase as
the clinical stage went up. Based on these
findings, it is supposed that patients with
higher serum levels of VEGF contained
more patients with advanced stage ofMPM.
These findings indicate that serum levels of
VEGF reflect the tumor burden or disease
progression of MPM. In such situation, the
prognostic significance should be examined
based on multivariate analysis as Cox re-
gression model, as in the report of Demirag
et al. At this point, we supposewe had better
be more cautious about the prognostic sig-
nificance of serum VEGF in MPM.
Nobukazu Fujimoto, MD, PhD
Kenichi Gemba, MD, PhD
Takumi Kishimoto, MD, PhD
Department of Respiratory Medicine
Okayama Rosai Hospital
Okayama, Japan
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How Do We Do It?
Another Optimal
Methodology for
Endobronchial
Ultrasound Sample
Handling
To the Editor:
We read with great interest the
article by Nakajima and Yasufuku1 in
the January issue of the Journal of
Thoracic Oncology. These authors re-
ported a methodology for analysis of
samples obtained by endobronchial ul-
trasound (EBUS), not only initially
developed for mediastinal staging of
non-small cell lung carcinoma
(NSCLC) but also widely used for the
initial diagnosis of mediastinal meta-
static lymph nodes. In this article, they
report a multidirectional analysis to
obtain precise diagnosis and molecular
testing, particularly emphasizing the criti-
cal use of freshly stored material.
We would like to report our own
experience of a cell aspirate freezing
method, allowing multiple cell analyses.
This method, although it presents certain
similarities with that described by Naka-
jima and Yasufuku, has a number of
notable differences.
Our sampling method has al-
ready been described.2 The entire pro-
cedure is performed by a cytopatholo-
gist for rapid on-site examination and
specimen handling. One to three
smears are performed for each aspi-
rate, and in the case of abundant ma-
terial, the extra aspirate is flushed into a
tube containing Roswell Park Memorial
Institute cell culture medium. After the
last aspirate, the needle is rinsed with
culture medium to obtain a cell suspen-
sion. Clots or tissue fragments, when
observed are removed, fixed in 10% for-
malin, and paraffin embedded for cell
blocks. Representativeness of cell sus-
pensions is checked by a stained cytos-
pin examination. Cell suspensions are
centrifuged, and cell pellets are frozen at
80°C in 20% dimethylsulfoxide
(Sigma, France) as usually performed
for cell lines: one to four frozen aliquots
are stored per specimen.
From March 16, 2007 to Decem-
ber 9, 2010, 450 patients underwent
conventional transbronchial needle aspi-
ration (TBNA; N  160) or EBUS-
guided TBNA (N  280). As systematic
storage at 80°C was started in May
2007, 425 cell aspirates have now been
frozen and stored (96% of all TBNA
performed over the last 38 months).
Two hundred sixteen of these stored
samples have been thawed for comple-
mentary techniques. The other samples
have been kept frozen for possible sub-
sequent analysis, if necessary.
When complementary tech-
niques are required, the samples are
thawed, and cytospin is performed to
check the quality of the cells. It must
be emphasized that this method of cell
freezing is usually associated with
very well-preserved cell morphology.
Depending on the suspected di-
agnosis, frozen and fresh cells can be
investigated by various methods. Flow
cytometry is used for the diagnosis of
lymphoma (lymphocyte immunotyp-
ing), small cell lung carcinoma (CD56
expression), or DNA ploidy. Tumor
cell differentiation markers (TTF1,
P63, CK7/CK20, estrogen receptors)
are studied in NSCLC or in patients
with a history of extrathoracic cancer,
either on smears, cytospins from fro-
zen cells or cell blocks. Molecular
analysis for EGFR and Ras mutations
is performed on thawed cell pellets in
NSCLC, and fluorescence in situ hy-
bridization analysis is performed on
cytospins from frozen cells.
In conclusion, we agree with Na-
kajima and Yasufuku that an optimal
methodology is essential for the man-
agement of specimens obtained by
EBUS-TBNA, particularly when rapid
on-site examination is not possible.
Fresh cell aspirates in cell culture me-
dium stored at 80°C in dimethylsulf-
oxide, which is a very simple method,
ensure optimal cell preservation for
morphology, allowing a wide range of
complementary techniques (flow cy-
tometry, molecular genotyping, etc.).
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